aneuploidy screening

aneuploidy screening

The testing of embryos for evidence of sex-linked diseases and structural chromosomal defects before their implantation in the uterus during assisted reproduction. Aneuploidy screening is one means of decreasing the risk of genetic diseases in implanted embryos.
References in periodicals archive ?
In the future, if appropriately validated and proven to be accurate, niPGT-A methods might even replace trophectoderm biopsy, reducing costs and risks of aneuploidy screening.
The researchers note that the clinical adoption of cfDNA sequencing for chromosomal aneuploidy screening has already had a global effect.
These genetic tests are possible during an IVF cycle: PGS 24-chromosome aneuploidy screening (includes gender identification), PGS 5-chromosome aneuploidy screening (includes gender identification), PGD for single gene disorders to avoid passing on hereditary disease (may be completed with 24-chromosome aneuploidy screening and/or HLA Matching), PGD for balanced translocations or inversions, includes 24-chromosome aneuploidy screening.
Growth in this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.
The main indication for performing invasive procedures was abnormal results of aneuploidy screening for trisomy 21, followed by maternal age, and fetal structural abnormality The fetal karyotype was altered in 154 (26.1%) cases.
Equitable use of NIPT for common aneuploidy screening in all women will require further reductions in test cost.
All pregnant women who attended the outpatient obstetric clinic were counselled about aneuploidy screening and were offered routine first-trimester screening.
Mateu et al., "Improving FISH diagnosis for preimplantation genetic aneuploidy screening," Human Reproduction, vol.
Detailed first- and second-trimester ultrasound scans, maternal characteristics and serum markers have been part of standard practice for aneuploidy screening for more than two decades.
The American College of Obstetricians and Gynecologists (ACOG) recommends that all women be offered aneuploidy screening during the first or second trimester of pregnancy.
Society for Maternal-Fetal Medicine Statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol.